Board Member
GeneDx Holdings Corp. (WGS)Equibles does not estimate personal net worth.
Get an email with a short summary when GeneDx Holdings Corp. publishes a filing, an earnings call transcript or a press release.
Get WGS alertsKatherine Stueland is recorded as Board Member at GeneDx Holdings Corp. (WGS) since January 1, 2022 and CEO at GeneDx Holdings Corp. (WGS). The newest filing on record that lists Katherine Stueland as CEO and Board Member at GeneDx Holdings Corp. (WGS) is dated April 30, 2026. The proxy statement of GeneDx Holdings Corp. reports total compensation of $13,547,219 for Katherine Stueland in fiscal 2025, including a base salary of $715,869. Disclosed compensation is on record for 4 fiscal years. Katherine Stueland has spoken on 18 earnings calls and 2 other investor events across 1 company, most recently for GeneDx Holdings Corp. on August 3, 2026. GeneDx Holdings Corp. is classified in the Diagnostics & Research industry within the Healthcare sector. Other leadership on record at GeneDx Holdings Corp. includes Eric Schadt (CEO and Board Member), Kevin Feeley (CFO), Richard Miao (CFO) and 7 others.
“Our team demonstrated incredible focus and agility to deliver a solid second quarter. We hit a new record, resulting more than 30,000 exome and genome tests in a quarter, which represents 32% year-over-year growth.”
“In the first quarter, GeneDx continued our mission of enabling everyone to live their healthiest life through genomics, leading the shift from diagnosing genetic conditions using multi-gene panels to the most comprehensive genetic test available, exome and genome.”
“I mean, GNDX has operated for 25 years and with a focus specifically in solving the world's hardest to diagnose cases around rare disease. For the past several years, really focused for the first time since 2021 with full commercial efforts behind our flagship whole exome and whole genome sequencing technology.”
“Catherine D' Thank you, Sabrina, and good morning, everyone. The fourth quarter was a strong finish to a transformative year for GNDX. We reported quarterly revenues of $121 million, bringing full-year revenues to $428 million, underpinned by 54% exome and genome revenue growth.”
2022-01-01–present
Last confirmed April 30, 2026
Start not stated–present
Last confirmed April 30, 2026
Diagnostics & Research · Healthcare
CEO, Board Member
2022-01-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | GeneDx Holdings Corp. (WGS) | Chief Executive Officer | $715,869 | $13,547,219 |
| 2024 | GeneDx Holdings Corp. (WGS) | CEO | $675,000 | $4,421,800 |
| 2023 | GeneDx Holdings Corp. (WGS) | CEO | $675,000 | $3,504,420 |
| 2022 | GeneDx Holdings Corp. (WGS) | Chief Executive Officer | $453,557 | $11,882,354 |
